kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - iné antineoplastické látky - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
lenalidomid teva b.v. 15 mg
teva b.v., holandsko - lenalidomid - 59 - immunopraeparata
lenalidomid teva b.v. 10 mg
teva b.v., holandsko - lenalidomid - 59 - immunopraeparata
lenalidomid teva b.v. 5 mg
teva b.v., holandsko - lenalidomid - 59 - immunopraeparata
lenalidomid teva b.v. 25 mg
teva b.v., holandsko - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 25 mg tvrdé kapsuly
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 15 mg tvrdé kapsuly
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 10 mg tvrdé kapsuly
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lenalidomid zentiva 5 mg tvrdé kapsuly
zentiva k.s., Česká republika - lenalidomid - 59 - immunopraeparata
lunsumio
roche registration gmbh - mosunetuzumab - lymfóm, folikulárny - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.